Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?
- Citation data:
Pharmacoepidemiology and drug safety, ISSN: 1099-1557, Vol: 21, Issue: 5, Page: 524-34
- Publication Year:
- Repository URL:
- https://works.bepress.com/leslie_harrold/46; https://escholarship.umassmed.edu/meyers_pp/542; http://kpresearchpublications.kp.org/handle/kp/8246
- Medicine; Antibodies, Monoclonal; Autoimmune Diseases; Immunoglobulin G; Infection; Health Services Research; Primary Care
Infliximab, a chimeric monoclonal anti-TNFα antibody, has been found to increase the risk of serious infections compared with the TNF receptor fusion protein etanercept in some studies. It is unclear whether the risk varies by patient characteristics. We conducted a study to address this question.